Gestational weight gain above current recommendations was a risk of infants with macrosomia or needing a cesarian delivery.
All articles by Lauren Grygotis
Degludec is noninferior to glargine in terms of incidence of major cardiovascular events in patients with type 2 diabetes at high cardiovascular risk.
At the end of a 3-month period, adolescents with type 2 diabetes experienced decreased HbA1c levels after using insulin pump therapy.
Women with subclinical hypothyroidism who undergo thyroid hormone treatment have a decreased risk of pregnancy loss, but may experience other pregnancy-related adverse outcomes.
The ACP has updated the 2012 guideline to provide clinical recommendations of oral pharmacologic treatment of type 2 diabetes.
The USPSTF recommends that children and adolescents older than age 6 years should be screened for obesity.
A uniform standard for thyroid-stimulating hormone reference limits could lead to frequent misclassification and incorrect choices for therapy.
All-cause, cardiovascular disease, and diabetes age-standardized mortality rates have decreased from 2000 to 2011.
Current exclusion criteria may impede women’s access to type 2 diabetes medication trials.